Canaccord Genuity Maintains Buy on Intra-Cellular Therapies, Lowers Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Sumant Kulkarni maintains a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) but lowers the price target from $101 to $100.
February 23, 2024 | 2:51 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on Intra-Cellular Therapies but lowers the price target from $101 to $100.
The adjustment in price target by Canaccord Genuity from $101 to $100, while maintaining a Buy rating, suggests a minor recalibration of expectations rather than a fundamental shift in the company's outlook. This slight adjustment is unlikely to have a significant short-term impact on the stock price, as the Buy rating remains unchanged, indicating continued confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100